Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
anticonvulsant |
| gptkbp:administeredBy |
oral route
|
| gptkbp:affects |
central nervous system
|
| gptkbp:approvedBy |
gptkb:European_Union
gptkb:United_States |
| gptkbp:ATCCode |
N03AG04
|
| gptkbp:CASNumber |
60643-86-9
|
| gptkbp:discoveredBy |
gptkb:Richard_H._Silverman
|
| gptkbp:hasMolecularFormula |
C4H7NO2
|
| https://www.w3.org/2000/01/rdf-schema#label |
gamma-vinyl-GABA
|
| gptkbp:inhibitedBy |
gptkb:GABA_transaminase
|
| gptkbp:IUPACName |
gptkb:(E)-4-Aminobut-2-enoic_acid
|
| gptkbp:marketedAs |
gptkb:Sabril
|
| gptkbp:otherName |
gptkb:vigabatrin
|
| gptkbp:PubChem_CID |
5665
|
| gptkbp:sideEffect |
fatigue
drowsiness visual field loss |
| gptkbp:usedFor |
epilepsy
infantile spasms |
| gptkbp:bfsParent |
gptkb:vigabatrin
|
| gptkbp:bfsLayer |
6
|